EUR-Lex Access to European Union law
This document is an excerpt from the EUR-Lex website
Document 52020XC0626(01)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2018 to 31 December 2019 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2018 to 31 December 2019 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2018 to 31 December 2019 (Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)
PUB/2020/486
OJ C 213, 26.6.2020, p. 1–2
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
26.6.2020 |
EN |
Official Journal of the European Union |
C 213/1 |
Summary of European Union decisions on marketing authorisations in respect of medicinal products from 1 October 2018 to 31 December 2019
(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))
(2020/C 213/01)
— Modification of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
29.10.2018 |
Eporatio |
ratiopharm GmbH Graf-Arco-Straße 3, 89079 Ulm, Deutschland |
EU/1/09/573 |
31.10.2018 |
29.10.2018 |
Viramune |
Boehringer Ingelheim International GmbH Binger Straße 173, 55216 Ingelheim am Rhein, Deutschland |
EU/1/97/055 |
31.10.2018 |
28.11.2018 |
Keppra |
UCB Pharma S.A. Allée de la Recherche 60, 1070 Bruxelles, Belgique/Researchdreef 60, 1070 Brussel, België |
EU/1/00/146 |
30.11.2018 |
28.11.2018 |
Pioglitazone Teva |
Teva B.V. Swensweg 5, 2031 GA Haarlem, Nederland |
EU/1/12/757 |
30.11.2018 |
28.11.2018 |
Pioglitazone Teva Pharma |
Teva B.V. Swensweg 5, 2031 GA Haarlem, Nederland |
EU/1/12/758 |
30.11.2018 |
28.11.2018 |
Spinraza |
Biogen Netherlands B.V. Prins Mauritslaan 13, 1171 LP Badhoevedorp, Nederland |
EU/1/17/1188 |
30.11.2018 |
20.12.2018 |
Vimizim |
BioMarin International Limited Shanbally, Ringaskiddy, County Cork, P43 R298, Ireland |
EU/1/14/914 |
24.1.2019 |
11.4.2019 |
Apidra |
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main, Deutschland |
EU/1/04/285 |
16.4.2019 |
15.4.2019 |
Orencia |
Bristol-Myers Squibb Pharma EEIG Plaza 254, Blanchardstown Corporate Park 2, D15 T867, Dublin 15, Ireland |
EU/1/07/389 |
17.4.2019 |
6.6.2019 |
Glustin |
Takeda Pharma A/S Dybendal Alle 10, 2630 Taastrup, Danmark |
EU/1/00/151 |
11.6.2019 |
27.6.2019 |
Xeljanz |
Pfizer Europe MA EEIG Boulevard de la Plaine 17, 1050 Bruxelles, Belgique/Pleinlaan 17, 1050 Brussel, België |
EU/1/17/1178 |
1.7.2019 |
23.8.2019 |
NutropinAq |
Ipsen Pharma 65 quai Georges Gorse, 92100 Boulogne-Billancourt, France |
EU/1/00/164 |
27.8.2019 |
23.9.2019 |
Zebinix |
Bial — Portela & Ca, SA À Av. da Siderurgia Nacional, 4745-457 S. Mamede do Coronado, Portugal |
EU/1/09/514 |
25.9.2019 |
29.10.2019 |
Inhixa |
Techdow Pharma Netherlands B.V. Strawinskylaan 1143, Toren C-11, 1077 XX Amsterdam, Nederland |
EU/1/16/1132 |
15.11.2019 |
22.11.2019 |
Flixabi |
Samsung Bioepis NL B.V. Olof Palmestraat 10, 2616 LR Delft, Nederland |
EU/1/16/1106 |
26.11.2019 |
— Modification of a marketing authorisation (Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted
Date of the decision |
Name of the medicinal product |
Holder of the marketing authorisation |
Number of the entry in the Community Register |
Date of notification |
26.4.2019 |
ERYSENG |
Laboratorios Hipra, S.A. Avda. La Selva, 135, 17170 Amer (Girona), España |
EU/2/14/166 |
30.4.2019 |
29.8.2019 |
BROADLINE |
Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein, Deutschland |
EU/2/13/157 |
2.9.2019 |
29.8.2019 |
VarroMed |
BeeVital GmbH Wiesenbergstrasse 19,A- 5164, Seeham, Österreich |
EU/2/16/203 |
2.9.2019 |
Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:
European Medicines Agency |
Domenico Scarlattilaan 6 |
1083 HS Amsterdam |
NETHERLANDS |